Sanofi News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

05.08.13	Sanofi Begins Late-stage Study Of Investigational Clostridium Difficile Vaccine (RTTNews)
01.08.13	Sanofi Q2 Profit Plunges On Charges, Generics; Cuts View (RTTNews)
01.08.13	Sanofi Q2 Profit Dips - Quick Facts (RTTNews)
01.08.13	Sanofi Q2 2013 - Interview with CEO Chris Viehbacher (Businesswire)
31.07.13	Sanofi's Nasacort AQ Nasal Spray Gets FDA Panel Backing (RTTNews)
25.10.12	Sanofi Q3 2012 - Interview with CFO Jérôme Contamine (Businesswire)
26.07.12	Sanofi CEO Chris Viehbacher Comments on Results for Q2 2012 (Businesswire)
27.04.12	Sanofi CFO Jérôme Contamine Comments on Q1 2012 Results (Businesswire)
08.02.12	Sanofi CEO Chris Viehbacher Comments on 2011 Results (Businesswire)
01.03.11	Genzyme Completes Sale of Pharmaceuticals Business to International Chemical Investors Group (Businesswire)
01.02.11	Supply & Demand Chain Executive Announces Three Volt Experts Among Its 2011 "Pros to Know" (Businesswire)
20.09.10	Synvisc Approved in Japan, Key Market for Viscosupplementation Products (Businesswire)
16.06.10	Shareholders Re-Elect All Members of Genzyme’s Board of Directors (Businesswire)
12.01.10	Genzyme Reports Fourth-Quarter Revenue (Businesswire)
08.01.10	Industry Veteran Ron Branning Joins Genzyme to Lead Global Product Quality (Businesswire)
07.01.10	Genzyme and Relational Investors Enter Into Mutual Cooperation Agreement (Businesswire)
08.12.09	Robert J. Bertolini Elected to Genzyme’s Board of Directors (Businesswire)
07.12.09	Genzyme Phase 3 Trial of Campath/Fludara Combination Shows Potential Benefit in Second-Line CLL (Businesswire)
06.10.09	Genzyme Receives FDA Complete Response Letter for Clolar (Businesswire)
23.09.09	Genzyme Provides Update on Cerezyme and Fabrazyme Supply (Businesswire)
10.07.09	Chattem to Webcast Presentation from the Oppenheimer 9th Annual Consumer, Gaming, Lodging & Leisure Conference (Businesswire)
01.06.09	Chattem to Webcast Presentation from William Blair & Company’s 29th Annual Growth Stock Conference (Businesswire)
19.03.09	Genzyme Receives Positive Opinion for European Approval of Renvela for Patients with Kidney Disease (Businesswire)
29.01.09	Fourth Quarter and Fiscal 2008 Results; Chattem Affirms Fiscal 2009 Guidance (Businesswire)
29.01.09	Fourth Quarter and Fiscal 2008 Results; Chattem Affirms Fiscal 2009 Guidance (Businesswire)
13.01.09	Genzyme Reports Strong Fourth-Quarter and 2008 Revenue Growth (Businesswire)
11.12.08	Progress by Genzyme, the Broad Institute and Medicines for Malaria Ventures Toward Developing Drug Candidates for Malaria Highlighted at Tropical Medicine Meeting (Businesswire)
09.12.08	Genzyme Reports Clolar® Data Further Supporting Potential of Product to Treat Adult AML Patients (Businesswire)
05.12.08	FDA Advisory Committee to Discuss Genzyme’s Synvisc-One PMA on Tuesday (Businesswire)
14.11.08	Chattem to Webcast Presentation from the Morgan Stanley Global Consumer & Retail Conference on November 18, 2008 (Businesswire)
10.09.07	Chattem to Webcast Presentation from the A.G. Edwards 2nd Annual Emerging Growth Conference on September 19, 2007 (Businesswire)
07.11.05	President & CEO of Memorial Hospital Joins Chattem, Inc.'s Board of Directors (Businesswire)
12.09.05	Chattem to Launch Icy Hot(R) Pro-Therapy(TM), a New Multi-Dimensional Topical Pain Care Product (Businesswire)
05.04.05	Chattem Executives to Speak at the SunTrust Robinson Humphrey 34th Ann (Businesswire)
10.03.05	Chattem, Inc. Schedules Release of First Quarter Fiscal 2005 Results a (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone
22.11.24		S&P 500-Handel aktuell: S&P 500 liegt letztendlich im Plus
22.11.24		Freundlicher Handel: NASDAQ 100 verbucht zum Ende des Freitagshandels Zuschläge
22.11.24		Gute Stimmung in New York: nachmittags Pluszeichen im S&P 500
22.11.24		Gewinne in New York: NASDAQ 100 präsentiert sich fester
22.11.24		Freundlicher Handel in New York: Dow Jones präsentiert sich am Freitagnachmittag fester
22.11.24		Börse New York in Grün: Dow Jones bewegt sich am Mittag im Plus

22.11.24

Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone

22.11.24

S&P 500-Handel aktuell: S&P 500 liegt letztendlich im Plus

22.11.24

Freundlicher Handel: NASDAQ 100 verbucht zum Ende des Freitagshandels Zuschläge

22.11.24

Gute Stimmung in New York: nachmittags Pluszeichen im S&P 500

22.11.24

Gewinne in New York: NASDAQ 100 präsentiert sich fester

22.11.24

Freundlicher Handel in New York: Dow Jones präsentiert sich am Freitagnachmittag fester